OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Sallman on the Examination of Magrolimab in AML

March 30th 2022

David Sallman, MD, discusses the examination of magrolimab in acute myeloid leukemia.

Dr. Cutler on the Examination of Itolizumab in aGVHD

March 30th 2022

Corey S. Cutler, MD, MPH, FRCPC, discusses the exploration of itolizumab in acute graft-versus-host disease.

Dr. Ramalingam on Investigating Osimertinib Combination Approaches in NSCLC

March 30th 2022

Suresh S. Ramalingam, MD, FACP, FASCO, discusses ongoing trials investigating osimertinib combination approaches in non-small cell lung cancer.

Dr. Mok on the Results of the U31402-A-U102 Trial in NSCLC

March 30th 2022

Tony SK Mok, MD, discusses the rationale for the phase 1 U31402-A-U102 trial in metastatic or unresectable non–small cell lung cancer.

Dr. Weksler on Addressing Disparities in Lung Cancer Care Delivery

March 26th 2022

Benny Weksler, MD, MBA, FACS, FACCP, discusses efforts being made at Allegheny Health Network Cancer Institute to address disparities in the delivery of care and its impact on the screening and treatment of lung cancer.

Dr. Redjal on Technological Advances in Neurosurgical Oncology

March 26th 2022

Navid Redjal, MD, FAANS, discusses technological advances that have impacted neurosurgical oncology.

Dr. Bechara on Minimally Invasive Bronchoscopic Approaches in Lung Cancer

March 26th 2022

Rabih I. Bechara, MD, FCCP, discusses how minimally invasive bronchoscopic approaches are utilized in lung cancer.

Dr. Koreth on Key Objectives of the EQUATOR Trial in aGVHD

March 24th 2022

John Koreth, MBBS, DPhil, discusses the key objectives of the phase 3 EQUATOR trial in acute graft-versus-host disease.

Dr. Kadia on the Utilization of Uproleselan with Chemotherapy in R/R AML

March 24th 2022

Tapan M. Kadia, MD, discusses the utilization of uproleselan with chemotherapy in relapsed/refractory acute myeloid leukemia.

Dr. Becker on the Rationale for Investigating Uproleselan in Combination with Chemotherapy in AML

March 24th 2022

Pamela S. Becker, MD, PhD, discusses the rationale for investigating uproleselan in combination with chemotherapy in relapsed/refractory acute myeloid leukemia.

Dr. Tripathy on the NALA Trial in HER2+ Breast Cancer With Brain Metastases

March 24th 2022

Debu Tripathy, MD, discusses the implications of results from the phase 3 NALA trial in patients with HER2-positive metastatic breast cancer with brain metastases.

Dr. DeAngelo on the Exploration of Uproleselan Plus Chemotherapy in R/R AML

March 23rd 2022

Daniel J. DeAngelo, MD, PhD, discusses the exploration of uproleselan plus chemotherapy in relapsed/refractory acute myeloid leukemia.

Dr. Asbun on the Importance of Multidisciplinary Approaches in Pancreatic Cancer

March 23rd 2022

Horacio J. Asbun, MD, discusses the importance of multidisciplinary approaches in pancreatic cancer.

Dr. Kotecha on MR-Guided Radiotherapy in Lung Cancer

March 23rd 2022

Rupesh Rajesh Kotecha, MD, discusses the use of magnetic resonance–guided radiotherapy in lung cancer.

Dr. Jhaveri on the TUXEDO-1 Trial in HER2+ Breast Cancer With Brain Metastases

March 23rd 2022

Komal Jhaveri, MD, FACP, discusses the implications of the phase 2 TUXEDO-1 trial in patients with HER2-positive metastatic breast cancer with brain metastases.

Dr. Mayadev on Atezolizumab Plus Chemoradiation in Locally Advanced Cervical Cancer

March 22nd 2022

Jyoti Mayadev, MD, discusses the phase 1 NRG-GY017 trial evaluating atezolizumab given as an immune primer or concurrently with extended field chemoradiation in patients with locally advanced, node-positive cervical cancer.

Dr. Slomovitz on the Key Objectives of the KEYNOTE-B21 Trial in High-Risk Endometrial Cancer

March 22nd 2022

Brian M. Slomovitz, discusses the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 trial.

Dr. Spiess on the Rationale for Investigating the MTAP Pathway in Genitourinary Cancers

March 21st 2022

Philippe E. Spiess, MD, MS, FACS, discusses the rationale for investigating the MTAP pathway in genitourinary cancers.

Dr. Traina on the Effects of Elacestrant in ER+, HER2- Breast Cancer

March 21st 2022

Tiffany A. Traina, MD, discusses the implications of the phase 3 EMERALD trial in advanced estrogen receptor–positive, HER2-negative breast cancer.

Dr. Jhaveri on Implications of the DESTINY-Breast03 Trial in HER2+ Breast Cancer

March 21st 2022

Komal Jhaveri, MD, FACP, discusses the implications of data from the phase 3 DESTINY-Breast03 trial in patients with HER2-positive metastatic breast cancer.